Beneficial Ownership Report · SCHEDULE 13D/A
Theravance Biopharma, Inc.
Beneficial Ownership Report
Structured filing — SCHEDULE 13D/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Theravance Biopharma, Inc.
- Company CIK
- 0001583107
- Street
- Ugland House, South Church Street
- City
- George Town
- State / country code
- E9
- Postal code
- KY1-1104
Statement details
- Amendment number
- 4
- Security class
- Ordinary Share $0.00001 Par Value
- Event date
- 09/23/2026
- Previously filed indication
- false
Authorized notification person 1
- Name
- Weiss Asset Management LP
- Phone
- (617) 778-7725
- Street
- c/o Georgiy Nikitin
- Street (continued)
- 222 Berkeley St., 16th Floor
- City
- Boston
- State / country code
- MA
- Postal code
- 02116
Reporting person 1
- Name
- Weiss Asset Management LP
- Reporting person CIK
- 0001357550
- No reporting person CIK indication
- N
- Citizenship / organization
- DE
- Reporting person type
- IA · PN
- Source of funds code
- WC
- Legal proceedings indication
- N
- Aggregate amount owned
- 0
- Percent of class
- 0.0
- Sole voting power
- 0
- Shared voting power
- 0
- Sole dispositive power
- 0
- Shared dispositive power
- 0
- Aggregate excludes certain shares
- N
- Comments
- Row 8, 10, 11, and 13: Please See Item 5
Reporting person 2
- Name
- BIP GP LLC
- Reporting person CIK
- 0001298983
- No reporting person CIK indication
- N
- Citizenship / organization
- DE
- Reporting person type
- HC · OO
- Source of funds code
- WC
- Legal proceedings indication
- N
- Aggregate amount owned
- 0
- Percent of class
- 0.0
- Sole voting power
- 0
- Shared voting power
- 0
- Sole dispositive power
- 0
- Shared dispositive power
- 0
- Aggregate excludes certain shares
- N
- Comments
- Row 8, 10, 11, and 13: Please See Item 5
Reporting person 3
- Name
- WAM GP LLC
- Reporting person CIK
- 0001504664
- No reporting person CIK indication
- N
- Citizenship / organization
- DE
- Reporting person type
- HC · OO
- Source of funds code
- WC
- Legal proceedings indication
- N
- Aggregate amount owned
- 0
- Percent of class
- 0.0
- Sole voting power
- 0
- Shared voting power
- 0
- Sole dispositive power
- 0
- Shared dispositive power
- 0
- Aggregate excludes certain shares
- N
- Comments
- Row 8, 10, 11, and 13: Please See Item 5
Reporting person 4
- Name
- Andrew M. Weiss
- Reporting person CIK
- 0001357643
- No reporting person CIK indication
- N
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Source of funds code
- WC
- Legal proceedings indication
- N
- Aggregate amount owned
- 0
- Percent of class
- 0.0
- Sole voting power
- 0
- Shared voting power
- 0
- Sole dispositive power
- 0
- Shared dispositive power
- 0
- Aggregate excludes certain shares
- N
- Comments
- Row 8, 10, 11, and 13: Please See Item 5
Item 1
Issuer
Theravance Biopharma, Inc.
Security title
Ordinary Share $0.00001 Par Value
Principal address
Comment
This Amendment No. 4 (this "Amendment") to Schedule 13D amends the Schedule 13D initially filed on April 12, 2023, (as amended prior to the date hereof, the "Prior Schedule 13D" and, as so amended by this Amendment, the "Schedule 13D") with respect to the items set forth below. Capitalized terms used without definition in this Amendment have the meanings assigned to them in the Prior Schedule 13D.
Item 5
Number of shares
See Item 5 (a).
Transactions
The Reporting Persons did not effect any transactions in the Issuer's Shares during the past 60 days. The Issuer's Shares were cancelled on September 23, 2026 in connection with the completion of the merger with Zymeworks Inc.
Other persons with an interest
Other than the Funds that directly hold the securities of the Issuer, and except as set forth in this Item 5, no other person is known to have the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale, of the Shares.
Date ownership ceased to exceed 5%
September 23, 2026
Percentage of class
Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The percentages set forth above have been calculated based on 51,918,754 shares of the Issuer's Shares issued and outstanding as of July 31, 2026, as reported in the Issuer's Form 8-K, filed with the SEC on September 18, 2026. Each of the Reporting Persons disclaims beneficial ownership of all of the Shares, except to the extent of its or his pecuniary interest therein, and the filing of this Schedule 13D/A shall not be deemed an admission of beneficial ownership of any Shares for any purpose. 0 Shares, representing 0.0% of the outstanding shares of the Issuer, are held by BIP. BIP GP LLC is the general partner of BIP. Weiss Asset Management LP is the investment manager of BIP. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. 0 Shares, representing 0.0% of the outstanding shares of the Issuer, are held by BGO. Weiss Asset Management LP is the investment manager of BGO. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. See cover page above for the aggregate number and percentage beneficially owned by each of the Reporting Persons.
Signature comments
** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.
Signature 1
- Reporting person
- Weiss Asset Management LP
- Signed
- Georgiy Nikitin
- Title
- GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
- Date
- 09/25/2026
Signature 2
- Reporting person
- BIP GP LLC
- Signed
- Georgiy Nikitin
- Title
- GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
- Date
- 09/25/2026
Signature 3
- Reporting person
- WAM GP LLC
- Signed
- Georgiy Nikitin
- Title
- GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
- Date
- 09/25/2026
Signature 4
- Reporting person
- Andrew M. Weiss
- Signed
- Georgiy Nikitin
- Title
- GEORGIY NIKITIN, ATTORNEY-IN-FACT FOR ANDREW M. WEISS**
- Date
- 09/25/2026
Company context
Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference® in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The Company is committed to creating/driving shareholder value.